Prevention of NAFLD and CVD Through Lifestyle Intervention
Cardiovascular Diseases (CVD) and Nonalcoholic Fatty Liver Diseases (NAFLD) Among Gallstone and Cholecystectomy Patients and the Impact of a Novel Diet and Muscle Training Program
Pontificia Universidad Catolica de Chile
300 participants
Sep 27, 2021
INTERVENTIONAL
Conditions
Summary
Prevention of non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) through lifestyle intervention (MAUCO+) is a clinical trial that aims to improve sarcopenia, aerobic capacity, body composition, and lipid profile, insulin resistance, cardiovascular risk, NAFLD, and maintain a healthier lifestyle. Through the implementation of physical activity and nutritional programs.
Eligibility
Inclusion Criteria2
- With and without gallstones disease
- With various degrees of NAFLD (none too severe)
Exclusion Criteria4
- Any significant comorbidity or physical limitation to undergo resistance exercise program
- Use of medications that alter muscle mass (e.g., corticosteroids)
- History of hepatitis B or C
- Use of hepatotoxic drugs
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Investigators will assess the efficiency of the intervention by measuring adherence to physical exercise and nutritional diet.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05618626